Request Discount

Orthostatic Hypotension Drugs Market (Product - Fludrocortisone, Midodrine Hydrochloride, Droxidopa, Pyridostigmine, Indomethacin, Nsaids ( Nonsteroidal Anti-inflammatory Drugs), and Other Products): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : August, 2019

  • Rep Id : HC0640

  • Category : Healthcare & Medical Devices

  • Status : Published

This report provides exclusive insights into the COVID-19 impact on the Orthostatic Hypotension Drugs Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Orthostatic Hypotension Drugs Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Orthostatic Hypotension Drugs Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.

A recent report published by Infinium Global Research on the orthostatic hypotension drugs market provides an in-depth analysis of segments and sub-segments in the global as well as regional orthostatic hypotension drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional orthostatic hypotension drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global orthostatic hypotension drugs market. According to the report, the global orthostatic hypotension drugs market is projected to grow at a healthy CAGR over the forecast period of 2019-2025.

Market Insight

Orthostatic hypotension is an excessive fall in blood pressure taking place early on the postural challenge when orthostatic stress overwhelms autonomic defenses. Orthostatic hypotension was the primary diagnosis in 35% of hospitalizations. The number of orthostatic hypotension-related hospitalizations increased steadily with age, and patients aged 75 years or older had the highest annual hospitalization rate, 233 per 100,000. Medication used to treat orthostatic hypotension is fludrocortisone (Florinef®), midodrine (ProAmatine®), or erythropoietin (Epogen®, Procrit®). These drugs work by increasing blood volume or by constricting the blood vessel.

The growing prevalence of chronic diseases has led to a significant rise in orthostatic hypotension primarily among the aging population. This factor majorly drives the growth of the orthostatic hypotension drugs market. There is an increased risk of orthostatic hypotension among people who consume medications, such as dopamine and dopamine agonists for the treatment of Parkinson's disease, antipsychotics antidepressants, and cardiovascular drugs. Several studies have reported that as many as 13% to 30% of elderly people have orthostatic hypotension. It is present in up to 20 percent of patients older than 65 years. Furthermore, orthostatic hypotension is a potential risk factor for vascular-related death, myocardial infarction, coronary heart disease, transient ischemic attack, falls, and fractures. In addition, rising income levels coupled with enhanced medical infrastructure are propelling the growth of the orthostatic hypotension drugs market. However, the high cost of these drugs hampers the growth of the orthostatic hypotension drugs market. Furthermore, increasing clinical trials on the development of new drugs for orthostatic hypotension are anticipated to create fruitful opportunities for the orthostatic hypotension drugs market.

Among the regions, North America holds the dominant share in the orthostatic hypotension drugs market. The U.S is the key revenue contributor in the North America orthostatic hypotension drugs market. In addition, orthostatic hypotension affects a huge population in the U.S. Furthermore, high per capita expenditure on healthcare, high disposable income, and reformation in the healthcare system such as reimbursement offerings are contributing to an enormous revenue in the North America orthostatic hypotension drugs market. Moreover, Asia Pacific is anticipated to grow at a significant pace over the forecast period owing to increasing occurrences of hypotension, changing dietary habits and sedentary lifestyle trends in emerging markets such as China and India.

Global Orthostatic Hypotension Drugs Market

Segment Covered

The report on global orthostatic hypotension drugs market covers segments such as product. On the basis of product, the sub-markets include fludrocortisone, midodrine hydrochloride, droxidopa, pyridostigmine, indomethacin, NSAIDs (nonsteroidal anti-inflammatory drugs), and other products. 

Companies Profiled:

The report provides profiles of the companies in the market such as Hoffmann-La Roche Limited, H. Lundbeck A/S, Amneal Pharmaceuticals Inc., Pfizer Inc., Novartis AG, Amgen, Inc., Mylan NV, and Shire plc. 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of orthostatic hypotension drugs market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount